



## Clinical trial results:

### Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)

#### Summary

EudraCT number	2020-000854-85
Trial protocol	FR ES DE IT Outside EU/EEA
Global end of trial date	22 June 2022

#### Results information

Result version number	v1 (current)
This version publication date	06 January 2023
First version publication date	06 January 2023

#### Trial information

##### Trial identification

Sponsor protocol code	CA045-020
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04730349
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussee de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-002492-PIP01-18
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 August 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 June 2022
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the safety and tolerability of bempegaldesleukin (bempeg; NKTR-214) in combination with nivolumab (nivo) in pediatric participants with malignant neoplasms that were refractory, or relapsed, or in participants for whom curative treatments are lacking.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 June 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Italy: 2
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	United States: 3
Worldwide total number of subjects	15
EEA total number of subjects	9

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	7
Adolescents (12-17 years)	8

Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

15 participants were treated in Part A. Study did not progress to Part B; therefore, no participants enrolled in Part B.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)

Arm description:

Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks

Arm type	Experimental
Investigational medicinal product name	Bempegaldesleukin (NKTR-214)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Bempegaldesleukin 0.006 mg/kg administered intravenously every 3 weeks

Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Nivolumab 4.5 mg/kg administered intravenously every 3 weeks

<b>Arm title</b>	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)
------------------	---

Arm description:

Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks

Arm type	Experimental
Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Nivolumab 360 mg administered intravenously every 3 weeks

Investigational medicinal product name	Bempegaldesleukin (NKTR-214)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection

## Dosage and administration details:

Bempegaldesleukin 0.006 mg/kg administered intravenously every 3 weeks

<b>Number of subjects in period 1</b>	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)
	Started	8
Completed	1	2
Not completed	7	5
Disease progression	6	4
Participant withdrew consent	1	-
Study drug toxicity	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)
-----------------------	--

Reporting group description:

Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks

Reporting group title	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)
-----------------------	---

Reporting group description:

Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks

Reporting group values	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)	Total
Number of subjects	8	7	15
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	7	0	7
Adolescents (12-17 years)	1	7	8
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	7.5	14.9	-
standard deviation	± 3.9	± 1.5	-
Sex: Female, Male Units: Participants			
Female	4	2	6
Male	4	5	9
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	0	1
Not Hispanic or Latino	4	6	10
Unknown or Not Reported	3	1	4
Race/Ethnicity, Customized Units: Subjects			
White	6	5	11
Black or African American	1	0	1
Other	1	2	3

## End points

### End points reporting groups

Reporting group title	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)
Reporting group description:	Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks
Reporting group title	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)
Reporting group description:	Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks

### Primary: Number of Participants with Adverse Events (AEs) - Part A

End point title	Number of Participants with Adverse Events (AEs) - Part A <sup>[1]</sup>
End point description:	Number of participants with adverse events (AEs). An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
End point type	Primary
End point timeframe:	From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

End point values	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants	8	7		

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Dose-Limiting Toxicities (DLTs) - Part A

End point title	Number of Participants with Dose-Limiting Toxicities (DLTs) - Part A <sup>[2]</sup>
End point description:	Number of participants with dose-limiting toxicities (DLTs). DLTs were collected and evaluated for Part A within the DLT evaluation period, which started on Cycle 1 Day 1 (first dose) and ended at Day 42 (42 days after first dose of the study therapy).

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 42 days after first dose

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants	0	0		

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants with Serious Adverse Events (SAEs) - Part A

End point title	Number of Participants with Serious Adverse Events (SAEs) - Part A <sup>[3]</sup>
-----------------	---

End point description:

Number of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants	6	5		

### Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Drug-Related Adverse Events - Part A

End point title	Number of Participants with Drug-Related Adverse Events - Part A <sup>[4]</sup>
-----------------	---

End point description:

Number of participants with drug-related adverse events. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

End point values	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants	6	6		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Participants with Adverse Events Leading to Discontinuation - Part A

End point title	Number of Participants with Adverse Events Leading to Discontinuation - Part A <sup>[5]</sup>
-----------------	---

End point description:

Number of participants with adverse events leading to discontinuation. An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants	2	3		

### Statistical analyses

No statistical analyses for this end point

#### Primary: Number of Participants Who Died - Part A

End point title	Number of Participants Who Died - Part A <sup>[6]</sup>
End point description:	Number of participants who died.
End point type	Primary
End point timeframe:	From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants	2	0		

### Statistical analyses

No statistical analyses for this end point

#### Primary: Maximum Observed Plasma Concentration (C<sub>max</sub>) - Part A

End point title	Maximum Observed Plasma Concentration (C <sub>max</sub> ) - Part A <sup>[7]</sup>
End point description:	Pharmacokinetics (PK) of bempegaldesleukin and nivolumab derived from serum concentration versus time data.
End point type	Primary
End point timeframe:	From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	()	()		

Notes:

[8] - Study terminated. PK samples not shipped for bioanalytical analysis. No PK data generated.

[9] - Study terminated. PK samples not shipped for bioanalytical analysis. No PK data generated.

### Statistical analyses

No statistical analyses for this end point

### Primary: Primary: Trough Observed Concentration (C<sub>trough</sub>) - Part A

End point title | Primary: Trough Observed Concentration (C<sub>trough</sub>) - Part A<sup>[10]</sup>

End point description:

Pharmacokinetics (PK) of bempegaldesleukin and nivolumab derived from serum concentration versus time data.

End point type | Primary

End point timeframe:

From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[11]</sup>	0 <sup>[12]</sup>		
Units: ng/mL				
geometric mean (geometric coefficient of variation)	()	()		

Notes:

[11] - Study terminated. PK samples not shipped for bioanalytical analysis. No PK data generated.

[12] - Study terminated. PK samples not shipped for bioanalytical analysis. No PK data generated.

### Statistical analyses

No statistical analyses for this end point

### Primary: Area Under the Plasma Concentration (AUC) - Part A

End point title	Area Under the Plasma Concentration (AUC) - Part A <sup>[13]</sup>
-----------------	--

End point description:

Pharmacokinetics (PK) of bempegaldesleukin and nivolumab derived from serum concentration versus time data.

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 6 months)

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

<b>End point values</b>	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	Part A: Bempegaldesle ukin (0.006 mg/kg)+ Nivolumab (360 mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[14]</sup>	0 <sup>[15]</sup>		
Units: hour*ng/mL				
geometric mean (geometric coefficient of variation)	()	()		

Notes:

[14] - Study terminated. PK samples not shipped for bioanalytical analysis. No PK data generated.

[15] - Study terminated. PK samples not shipped for bioanalytical analysis. No PK data generated.

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Participants assessed for all-cause mortality from first dose to study completion (up to approximately 13 months). SAEs and NSAEs were assessed from first dose to 150 days after last dose of study therapy (up to approximately 11 months).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	25.0

### Reporting groups

Reporting group title	Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)
-----------------------	---

Reporting group description: -

Reporting group title	Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)
-----------------------	--

Reporting group description: -

<b>Serious adverse events</b>	Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)	Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 7 (71.43%)	8 / 8 (100.00%)	
number of deaths (all causes)	2	7	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	2 / 7 (28.57%)	6 / 8 (75.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 6	
Injury, poisoning and procedural complications			
Skin wound			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Brain oedema			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Seizure			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza like illness			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 7 (28.57%)	2 / 8 (25.00%)	
occurrences causally related to treatment / all	2 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			

subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hypoxia</b>			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pleural effusion</b>			
subjects affected / exposed	1 / 7 (14.29%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonitis</b>			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory failure</b>			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Renal and urinary disorders</b>			
<b>Nephrotic syndrome</b>			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Arthralgia</b>			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal chest pain</b>			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)	Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 7 (100.00%)	8 / 8 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour haemorrhage			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences (all)	0	1	
Chest pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Chills			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	2 / 7 (28.57%)	4 / 8 (50.00%)	
occurrences (all)	8	4	
Generalised oedema			

subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1	
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Pyrexia subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 6	2 / 8 (25.00%) 3	
Pain subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 8 (12.50%) 1	
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Reproductive system and breast disorders Scrotal oedema subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1	
Nasal congestion subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	0 / 8 (0.00%) 0	
Lung disorder subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Hypoxia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 8 (12.50%) 1	
Pulmonary embolism			

subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Pneumothorax subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Pneumonitis subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Pleural effusion subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Rhinitis allergic subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Psychiatric disorders Behaviour disorder subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Insomnia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Sleep disorder subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Investigations C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 2	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Aspartate aminotransferase increased			

subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 3	0 / 8 (0.00%) 0	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 4	0 / 8 (0.00%) 0	
Lymphocyte count decreased subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 8	1 / 8 (12.50%) 1	
Neutrophil count decreased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 4	0 / 8 (0.00%) 0	
White blood cell count decreased subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 6	0 / 8 (0.00%) 0	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 2	0 / 8 (0.00%) 0	
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 8 (12.50%) 1	
Ligament sprain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Cardiac disorders			
Sinus bradycardia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Sinus tachycardia subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	0 / 8 (0.00%) 0	
Nervous system disorders			
Dysgeusia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Dizziness			

subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	1 / 8 (12.50%) 1	
Ataxia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Presyncope subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Neuralgia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Headache subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 3	3 / 8 (37.50%) 3	
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 7	1 / 8 (12.50%) 1	
Eosinophilia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Febrile neutropenia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Ear and labyrinth disorders			
Hypoacusis subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Eye disorders			
Eye pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Photophobia			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
<b>Gastrointestinal disorders</b>			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1	
Constipation subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	0 / 8 (0.00%) 0	
Nausea subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 5	0 / 8 (0.00%) 0	
Tooth discolouration subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Vomiting subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 5	2 / 8 (25.00%) 2	
<b>Skin and subcutaneous tissue disorders</b>			
Photosensitivity reaction subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Dry skin subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Dermatitis allergic subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Rash maculo-papular subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 3	0 / 8 (0.00%) 0	
Urticaria subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Rash			

subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	3 / 8 (37.50%) 4	
Pruritus subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1	
Renal and urinary disorders Urinary incontinence subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 8 (12.50%) 1	
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1	
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Bone pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Myalgia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Muscle spasms subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 8 (0.00%) 0	
Pain in extremity subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	1 / 8 (12.50%) 1	
Infections and infestations			

Lymphangitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences (all)	0	1	
Cystitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Conjunctivitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences (all)	0	1	
COVID-19			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Vaginal infection			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Rhinitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	2	0	
Pharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	3 / 7 (42.86%)	1 / 8 (12.50%)	
occurrences (all)	3	1	
Hyperglycaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Hypoalbuminaemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 8 (12.50%)	
occurrences (all)	0	1	
Hypocalcaemia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 8 (0.00%)	
occurrences (all)	2	0	
Hypophosphataemia			

subjects affected / exposed	2 / 7 (28.57%)	0 / 8 (0.00%)	
occurrences (all)	2	0	
Hyponatraemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Hypokalaemia			
subjects affected / exposed	3 / 7 (42.86%)	0 / 8 (0.00%)	
occurrences (all)	5	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 November 2021	Updated the minimum days from "100" to "150" days following discontinuation of drug for collection of all serious adverse events (SAEs) and Non-Serious Adverse Events (NSAEs).

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study was terminated on 22-Jun-2022. This results disclosure report provides analyses from CA045-020 Part A safety analyses only. Part B of the study (expansion phase) did not enroll any participants.

Notes: